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Brca1 and Brca2 germline mutations are frequently observed in
women presenting breast carcinoma as part of an hereditary cancer
susceptibility syndrome (Ford et al, 1998). The histological pheno-
type of Brca-associated breast tumours differs from that of sporadic
cases: Brca1-associated tumours generally present as poorly differ-
entiated and highly mitotic carcinomas (Jacquemier et al, 1995;
Lakhani et al, 1998) whereas Brca2 tumours were reported to
present a high (Agnarsson et al, 1998) or a low (Lakhani et al,
1998) mitotic index. However, no characteristic immunophenotype
of these lesions has been reported so far (Robson et al, 1998), and
little data are available regarding the biological mechanisms
involved in the development of tumours associated with Brca1 or 2
gene mutations. Using animal models, it was recently reported that
the disruption of the Brca1 alleles specifically in mouse mammary
epithelium leads to increased apoptosis and to tumour formation
(Xu et al, 1999). These findings prompted us to analyse the expres-
sion of the antiapoptotic bcl-2 and of the proapoptotic p53 genes in
a series of Brca1- and Brca2-associated breast carcinomas, together
with mitotic and apoptotic indexes, and to compare these values to
those obtained in sporadic cancers.
This analysis showed that, whereas no difference in p53 expres-
sion was observed between the different groups, Brca1-associated
tumours dysplayed a low rate of bcl-2 expression and high mitotic
and apoptotic indexes. The decrease in bcl-2 expression was found
to be independent from hormone receptor status and may account
for the high apoptotic and proliferative rates observed in Brca1-
associated tumours.
MATERIAL AND METHODS
Sixteen women affected with a breast carcinoma before the age of
36 were detected to be carriers of a germline Brca1 mutation
through the Brca1 analysis of a series of 123 early-onset consecu-
tive cases as reported in a previous study (Ansquer et al, 1998).
The corresponding 16 tumours were analysed and correspond to
the group of cases. A first control group was constituted by a series
of 39 women from the early-onset series identified as non-Brca1
carriers. Tumours of 36 sporadic cases, untested for Brca1 and
Brca2 mutation, constituted a second control group. The former
group has been chosen to avoid a possible bias related to the fact
that tumours occurring in young women might present a character-
istic immunophenotype independently from their Brca status. In
addition, the tumours of four women belonging to the early-onset
breast carcinomas series and identified as carrier of a germline
Brca2 mutation were also studied. p53 and bcl-2 gene expression
was assessed by immunohistochemistry using anti-p53 (D0–7) and
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doi: 10.1054/ bjoc.2000.1438, available online at http://www.idealibrary.com on anti-Bcl-2 (124) monoclonal antibodies (Dako A/S, Glostrup,
Denmark). The threshold of positivity was 5% of malignant
stained cells for p53 and 1% for Bcl-2. Proliferation rate was deter-
mined by counting the number of mitotic features in ten successive
microscopic fields at G ´ 400, as recommended for the evaluation
of the Nottingham histological grade (Elston and Ellis, 1991;
Genestie et al, 1998). Apoptotic index was assessed on haema-
toxylin–eosin-coloured histological sections by counting nuclear
and/or cytoplasmic features characterising the apoptotic process
(Bessis, 1964; Cummings et al, 1997). In every case, a tumour area
presenting the highest number of apoptotic features was deter-
mined at low magnification, then analysed at high power field (G ´
400). After image capture, apoptotic features were pointed on the
screen and scored using an image analysis system (Perfect Image;
Clara Vision, Orsay, France). The apoptotic index was defined as
the ratio between this count and the total number of invasive
malignant cells. The counting was performed on successive fields
when less than 100 invasive malignant cells were present on a
single field.
The association between Brca1 gene mutation and tumour char-
acteristics was evaluated using the Chi-squared test with Yate’s
correction when necessary for discrete variables (tumour size,
nodal status, histological grade, hormonal status, bcl-2 status, p53
status) and the Mann–Whitney test for continuous variables (age,
mitotic index, apoptotic index). Logistic regression was used to
assess the independent association of factors for Brca1 gene muta-
tion identified in univariate analysis, in a group of tumours for
which all clinical and pathological data were available (52
tumours), i.e. 13 cases with Brca1 mutation and the 39 controls
with no Brca1 mutation. All variables with P value < 0.05 were
introduced in the initial multivariate model (excepted mitotic and
apoptotic indexes) and deleted through a backward procedure.
Variables with a significance level of 0.05 were kept in the final
model.
RESULTS
Our analysis showed that a higher histological grade (P = 3.10–4), a
higher mitotic index (P = 9.10–3), a higher apoptotic index (P =
2.10–2) and a lower rate of oestrogen receptor positivity (P = 10–3)
were observed in Brca1-associated breast cancers than in controls
(Table 1). A slight positive correlation was found between mitotic
and apoptotic indexes (r = 0.28, P = 0.045).
The immunohistochemical analysis found no significant differ-
ence in p53 immunostaining between the four groups of tumours.
In contrast, a significant difference in bcl-2 expression was found
between cases and either control groups (Figure 1). The rate of bcl-
2-positive tumours was lower (31%) in Brca1-associated carci-
nomas than in sporadic tumours (77%) (P = 2.10–3). This
difference was even more striking in comparison with the rate of
bcl-2-positive tumours observed in young women without Brca1
mutation (90%) (P < 10–3). The four cases of Brca2-associated
carcinoma were found to be positive. The mean number of labelled
cells was 56% in the group of sporadic tumours and 45% in
tumours with no Brca1 mutation. In contrast, a complete absence
of labeling was observed in 11 of the 16 cases of Brca1-associated
carcinomas. A weak staining of 5% of the tumour cells was
observed in one case whereas the remaining four cases exhibited
40–80% of labelled cells. The negative association of bcl-2
expression and Brca1-mutation remained significant after
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Table 1 Clinicopathological characteristics of patients and tumours according to the Brca status
Parameters Cases Controls P a
Brca1 Brca2 No Brca1 Sporadic
mutation mutation mutation tumours
Number of cases 16 4 39 36 –
Patient’s age
median 34 50.5 33 62.5 –
mini–maxi 25–47 49–52 21–36 31–80
Tumour size
≤20 mm 5 (31.2%) 2 (50%) 17 (43.6%) 9 (25%)
>20 mm 11 (68.8%) 2 (50%) 22 (56.4%) 27 (75%) ns
Node status
N0 6 (37.5%) 3 (75%) 26 (66.7%) 26 (72.2%)
N1 10 (62.5%) 0 13 (33.3%) 9 (25%) 4.6´10–2
N2 0 1 (25%) 0 1 (2.8%)
Histological grade
I 0 0 3 (7.7%) 7 (19.4%)
II 4 (25%) 1 (25%) 27 (69.2%) 16 (44.4%) 3.10–4
III 12 (75%) 3 (75%) 9 (23.1%) 13 (36.2%)
Mitotic indexb 14.5 5.5 4 8 9.10–3
Apoptotic indexb 10 9 7 nd 2.10–2
Hormonal status
ER-positive 3 (21.4%) 4 (100%) 27 (71.1%) 26 (74.3%) 10–3
PR-positive 7 (46.7%) 3 (75%) 28 (73.7%) 23 (65.7%) ns
nd 3 1 1
Bcl-2 status
positive cases 5 (31%) 4 (100%) 35 (90%) 27 (77%) <10–3c
P53 status
positive cases 9 (56.2%) 0 24 (61.5%) 13 (38.2%) ns
nd 2
aBrca1 cases vs no Brca1 mutation; bmedian of indexes; cChi-squared test with Yate’s correction; nd = not determined; ns = not
significantadjustment on oestrogen receptor status. In multivariate logistic
regression analysis, low expression of bcl-2 (odds ratio (OR) 13.9;
95% CI 2.6–76.9) and high histological grade (OR 7.1; 95% CI
1.3–38.8) were significant predictive variables associated with the
presence of Brca1 gene mutation (Table 2). No significant correla-
tion was observed between p53 and Bcl-2 immunostaining, either
in cases or in controls.
DISCUSSION
Our study shows that most Brca1-associated breast carcinomas are
characterized by high mitotic and apoptotic rates, and by a decrease of
bcl-2 expression. These biological traits seem not to be shared by
Brca2-associated tumours and not related to oestrogen receptor and/or
to p53 status. In an analysis of the immunophenotype of Brca-
associated tumours, only a slight decrease of bcl-2 expression was
found in familial cancers in comparison with the level observed in
controls (Robson et al, 1998). However, in this work, Brca1- and
Brca2-tumours were included in the same group, and this could
account for the negativity of the result. Recent data emphasize that
different molecular pathogenetic processes characterize Brca1- and
Brca2-associated tumours (Armes et al, 1999), and this is in agree-
ment with our data on distinctive bcl-2-expression in these two
tumour types.
High levels of bcl-2 expression have been observed in 75–80%
of cases of sporadic breast cancers (Leek et al, 1994; Silvestrini et
al, 1994; Hellemans et al, 1995). This expression was found to be
associated with the presence of favourable prognostic features
(Joensuu et al, 1994) and with the expression of oestrogen and
progesterone receptors (Barghava et al, 1994; Gee et al, 1994;
Leek et al, 1994; Silvestrini et al, 1994; Hellemans et al, 1995;
Charpin et al, 1997).
Since  Brca1-associated breast carcinomas are frequently
oestrogen receptor negative, poorly differentiated tumours, and
since a positive association exists between the respective expres-
sion of oestrogen receptor (ER) and bcl-2, the down-regulation of
bcl-2 in  Brca1-associated carcinomas might merely reflect the
down regulation of ER in this type of tumour. In our study, the loss
of  bcl-2 expression characterizing Brca1-associated carcinomas
behaved as a biological trait independent from the ER status of the
tumours. Definitive conclusions cannot be drawn from this multi-
variate analysis considering the limited number of cases included
in this series. However, it is worth mentioning that in multivariate
analyses of prognostic factors characterizing large series of axil-
lary node-positive breast tumours, the lack of bcl-2 expression was
found associated with a poor outcome of the disease, indepen-
dently from the ER status (Hellemans et al, 1995; Berardo et al,
1998).
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Figure 1 Histological aspects of sporadic invasive ductal carcinoma (A1), Brca1-associated (B1) and Brca2-associated (C1) carcinomas. Immunostainings of
bcl-2 in these cases. High level of bcl-2 expression in sporadic cancer (A2) and in Brca2-associated carcinoma (C2). No expression detected in 
Brca1-associated carcinoma (B2)The molecular mechanisms of action of Brca1 in the tumour
process are poorly understood. The observation of increased
apoptosis in mouse mammary tissue triggered by the inactivation
of the two copies of the Brca1 gene (Xu et al, 1999) suggest that
the Brca1 gene products could function as transcriptional regula-
tors of (Yang and Lippman, 1999). The anti-apoptotic bcl-2 might
be one of the target genes for Brca1 in such mechanisms. Our
present data reporting a down-regulation of bcl-2 and a high
apoptotic index of Brca1-associated carcinomas support this
hypothesis. Another line of evidence indicates that Brca1 plays a
positive role in the control of cell growth (Gudas et al, 1996). bcl-
2 gene product could also act as a second messenger in this
control: an inhibitory effect of entry into the cell cycle has been
reported for bcl-2 (O’Reilly et al, 1996). and this effect was found
genetically separable from the functions of the protein in cell
survival (Huang et al, 1997). The high proliferative rate observed
in  Brca1-, but not in Brca2-associated tumours (Armes et al,
1999), might thus be related to the respective levels of bcl-2
expression in these tumours. It is worth mentioning that a positive
link between proliferation and apoptosis has already been
observed in carcinomas of the breast (Dowsett et al, 1999), and
that the loss of bcl-2 has been found to be associated with both
increased apoptosis and increased proliferative rates in sporadic
breast cancers (van Slooten et al, 1998). In such cases, it would be
of interest to determine whether this loss was associated with a
down-regulation of Brca1, the implication of which in the
progression of sporadic breast carcinomas is also a matter of spec-
ulation (Yang and Lippman, 1999).
The similarity in p53 immunostaining between Brca1-and non
Brca1-associated tumours is in agreement with our previous
results reporting a similar pattern in p53 mutations in these two
groups of tumours (Schlichtholz et al, 1998). These results are at
discrepancy with data reporting a high rate of p53 mutation in a
small group of Brca1-associated carcinomas (Crook et al, 1997). It
is worth mentioning that a very large diversity of p53 mutational
patterns is observed among cohorts of sporadic breast cancers
(Hartmann et al, 1997). These variations may also concern
familial tumours and thus account, at least in part, for the discrep-
ancies observed between the rates of p53 alterations in these
tumours. Furthermore, the biological consequence of p53 cell
accumulation, as determined by immunohistochemistry, is unclear
and the link between p53-positive immunostaining and gene
mutation is inconstant in breast cancers (Sjögren et al, 1996). No
correlation was observed between p53 and bcl-2 immunostaining
in our study, a result already reported by others (Silvestrini et al,
1996).
In conclusion, a low bcl-2 expression and high proliferative and
apoptotic rates characterize most Brca1-associated breast carci-
nomas. The analysis of a large series of cases including the assess-
ment of the expression of bcl-2, of Brca1 and of biological
parameters associated with cell death and proliferation, should
help to determine whether alterations of the functions of Brca1
gene product were responsible for the down-regulation of bcl-2,
and thus for the high proliferative rate and increased apoptosis
observed in Brca1-associated carcinomas.
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